Literature DB >> 21468693

The multifaceted roles of USP7: new therapeutic opportunities.

Benjamin Nicholson1, K G Suresh Kumar.   

Abstract

The deubiquitylating enzyme USP7 (HAUSP) sits at a critical node regulating the activities of numerous proteins broadly characterized as tumor suppressors, DNA repair proteins, immune responders, viral proteins, and epigenetic modulators. Aberrant USP7 activity may promote oncogenesis and viral disease making it a compelling target for therapeutic intervention. Disclosed drug discovery programs have identified inhibitors of USP7 such as P005091 with cellular proof of concept and anti-proliferative activity in cancer models. Taken together, USP7 inhibitors hold promise as a new strategy for the treatment of disease.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21468693     DOI: 10.1007/s12013-011-9185-5

Source DB:  PubMed          Journal:  Cell Biochem Biophys        ISSN: 1085-9195            Impact factor:   2.194


  119 in total

Review 1.  SCF ubiquitin ligase-targeted therapies.

Authors:  Jeffrey R Skaar; Julia K Pagan; Michele Pagano
Journal:  Nat Rev Drug Discov       Date:  2014-11-14       Impact factor: 84.694

Review 2.  USP7: Structure, substrate specificity, and inhibition.

Authors:  Alexandra Pozhidaeva; Irina Bezsonova
Journal:  DNA Repair (Amst)       Date:  2019-02-16

Review 3.  Decision for cell fate: deubiquitinating enzymes in cell cycle checkpoint.

Authors:  Key-Hwan Lim; Myoung-Hyun Song; Kwang-Hyun Baek
Journal:  Cell Mol Life Sci       Date:  2016-01-13       Impact factor: 9.261

4.  Genome-Wide Association Study of Susceptibility Loci for T-Cell Acute Lymphoblastic Leukemia in Children.

Authors:  Maoxiang Qian; Xujie Zhao; Meenakshi Devidas; Wenjian Yang; Yoshihiro Gocho; Colton Smith; Julie M Gastier-Foster; Yizhen Li; Heng Xu; Shouyue Zhang; Sima Jeha; Xiaowen Zhai; Takaomi Sanda; Stuart S Winter; Kimberly P Dunsmore; Elizabeth A Raetz; William L Carroll; Naomi J Winick; Karen R Rabin; Patrick A Zweidler-Mckay; Brent Wood; Ching-Hon Pui; William E Evans; Stephen P Hunger; Charles G Mullighan; Mary V Relling; Mignon L Loh; Jun J Yang
Journal:  J Natl Cancer Inst       Date:  2019-12-01       Impact factor: 13.506

5.  Deubiquitination of Tip60 by USP7 determines the activity of the p53-dependent apoptotic pathway.

Authors:  Ashraf Dar; Etsuko Shibata; Anindya Dutta
Journal:  Mol Cell Biol       Date:  2013-06-17       Impact factor: 4.272

6.  The Deubiquitinating Enzyme USP7 Regulates Androgen Receptor Activity by Modulating Its Binding to Chromatin.

Authors:  Shu-Ting Chen; Maiko Okada; Ryuichiro Nakato; Kosuke Izumi; Masashige Bando; Katsuhiko Shirahige
Journal:  J Biol Chem       Date:  2015-07-14       Impact factor: 5.157

Review 7.  Flickin' the ubiquitin switch: the role of H2B ubiquitylation in development.

Authors:  Duncan Edward Wright; Chen-Yi Wang; Cheng-Fu Kao
Journal:  Epigenetics       Date:  2011-10-01       Impact factor: 4.528

8.  USP7 controls Chk1 protein stability by direct deubiquitination.

Authors:  Ignacio Alonso-de Vega; Yusé Martín; Veronique A J Smits
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

9.  Supervillin-mediated suppression of p53 protein enhances cell survival.

Authors:  Zhiyou Fang; Elizabeth J Luna
Journal:  J Biol Chem       Date:  2013-02-04       Impact factor: 5.157

10.  Identification and Structure-Guided Development of Pyrimidinone Based USP7 Inhibitors.

Authors:  Colin R O'Dowd; Matthew D Helm; J S Shane Rountree; Jakub T Flasz; Elias Arkoudis; Hugues Miel; Peter R Hewitt; Linda Jordan; Oliver Barker; Caroline Hughes; Ewelina Rozycka; Eamon Cassidy; Keeva McClelland; Ewa Odrzywol; Natalie Page; Stephanie Feutren-Burton; Scarlett Dvorkin; Gerald Gavory; Timothy Harrison
Journal:  ACS Med Chem Lett       Date:  2018-02-21       Impact factor: 4.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.